Diana Ernst, RPh

Editorial Director https://www.infectiousdiseaseadvisor.com

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

HIV/AIDS

Pharmacokinetic Data Support Potential Use of Emtricitabine and Tenofovir Alafenamidefor HIV PrEP

Diana Ernst, RPh

July 26, 2019

Descovy reached intracellular drug concentration levels above the estimated protective threshold significantly faster than Truvada.

HIV/AIDS

FDA Eliminates REMS for Truvada, PrEP Generics

Diana Ernst, RPh

July 10, 2019

In 2012, the FDA established the Truvada REMS for PrEP which required manufacturers to provide training materials, now that is no longer needed.

Influenza

Baloxavir Safe, Effective in Pediatric Influenza Study

Diana Ernst, RPh

July 10, 2019

According to results from the MINISTONE-2 trial, baloxavir marboxil (Xofluza) was found to be safe and effective in children 1 to less than 12 years old with an influenza infection.

Hepatitis

ACIP Votes to Update Hepatitis A Vaccination Recommendations

Diana Ernst, RPh

July 9, 2019

The Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices (ACIP) has voted to recommend that pediatric patients (2 to 18 years old) who have not previously received hepatitis A vaccine be routinely vaccinated at any age. Currently, the CDC recommends routine hepatitis A vaccination for children 12 to 23 months of…

HIV/AIDS

Bictegravir/Emtricitabine/Tenofovir alafenamide Approved to Treat Pediatric Patients With HIV

Diana Ernst, RPh

June 21, 2019

The pediatric approval was based on data from an open label, single arm trial that evaluated the efficacy, safety, and pharmacokinetics of Biktarvy in virologically suppressed children (6 to <12 years old; n=50) and adolescents (12 to <18 years old; n=50).

First App Launched to Identify Drug Shortages

Emerging Treatments

FDA Panel Votes on Treatment for Extensively Drug Resistant, Multidrug Resistant TB

Diana Ernst, RPh

June 11, 2019

The FDA’s Antimicrobial Drugs Advisory Committee voted in favor of pretomanid, as part of a combination regimen with bedaquiline and linezolid, for the treatment of pulmonary extensively drug resistant, treatment intolerant, or nonresponsive multidrug resistant tuberculosis.

Respiratory

PPD Shortage Prompts CDC to Issue New Recommendations for TB Testing

Diana Ernst, RPh

June 10, 2019

The CDC announced an expected 3 to 10 month shortage of Aplisol (tuberculin purified protein derivative [PPD], diluted), used as an aid in the diagnosis of tuberculosis.